admin – Page 3135 – Get News Story

Cornelius House Painter Transforms Homes And Businesses For 15 Years

Travers Painting specializes in residential and commercial painting, offering a range of services that include interior and exterior painting, cabinet painting and refinishing, as well as deck and door staining. The firm’s expertise extends to home repairs, including drywall repair, exterior wood rot repair, and interior trim repair.

Chris Travers of Travers Painting is pleased to announce that the Cornelius house painter has been transforming homes and businesses for more than fifteen years. CEO and Painter Chris Travers is highly rated and recommended, with many 5-star Google reviews from satisfied customers. The company is recognized for its superior craftsmanship, timeliness, and efficiency, as well as its full-service repairs and painting.

The expertise of professional painters is marked by attention to detail and the use of high-quality paints and materials. The company’s reputation is built on consistently completing projects on time and adhering to schedules. The knowledge and experience of the professionals have made Travers Painting and Construction a one-stop shop for painting and home repairs. Travers is a professional painting company licensed and insured in the state of North Carolina.

Chris Travers explains, “We pride ourselves on delivering exceptional quality and craftsmanship for every project. Homeowners and businesses have learned that they are able to trust our expertise. My approach to each project, whether it be large or small, is simply to treat people the way that I would want to be treated. From start to finish, our skilled team ensures timely completion, clear communication, and a clean workspace. We can only stand behind our work when we use the highest quality paint and stains for our projects. Our team has decades of paint and construction experience. We work well together to increase speed and efficiency. To date, we have completed more than 100 projects.”

The one-stop painting and repair team boasts a diverse portfolio that encompasses both residential and commercial painting projects. The professional painters possess the expertise to complete interior and exterior painting projects with equal customer satisfaction. Some of the exterior painting projects include brick and siding painting, with a materials list that ranges from vinyl to metal to Hardie Board. The painters complete garage door painting to make the garage door stand out or match colors. They also repair and paint exterior trim pieces. Porches, decks, and railings are repaired, stained, and painted as desired by the customers. Doors and shutters can be brought up to code with quality paints and stains.

Additional details are available at https://traverspainting.com.

The whole home interior painting projects include new builds or remodels; the team can paint and stain it all. Professionals can also handle small jobs, such as bedrooms or primary living spaces. Customers can save money by remodeling existing cabinets by painting and refinishing. The ceiling and trim painting projects include work on these areas to become a focal point or to match the overall space. Drywall and trim repairs include fixing dents and cracks before painting to restore the features to their original appearance.

“I have always wanted to work for myself,” Chris continues. “From the time I was a youngster, my brother and I spent time brainstorming different business ideas that we could implement ourselves. When I relocated from New York City to the Huntersville, North Carolina area I determined to launch Travers Painting and Construction. I have worked diligently to ensure that my business has a reputation for creating quality work, on-time, and for a reasonable price.”

The experienced team takes pride in delivering flawless finishes with attention to detail, using high-quality materials to ensure lasting beauty and durability. Every project is completed with precision, care, and a commitment to excellence. The customers’ time is respected by staying on schedule and completing efficiently without compromising quality. From beginning to completion, the streamlined process ensures minimal disruption to the customer’s home or business. Beyond painting, the team provides expert home repairs, including drywall repair, wood rot restoration, and trim repairs.

About the Company:

Travers Painting offers the depth of experience to be Lake Norman’s recognized painting company. For more than 15 years, the quality of the painters and the products they use have been noted by customers. The size of projects in the company’s portfolio varies from minor repairs to whole-house projects.

Media Contact
Company Name: Travers Painting and Construction
Contact Person: Chris Travers
Email: Send Email
Phone: (704) 249-9227
Address:19125 Chandlers Landing Dr
City: Cornelius
State: NC 28031
Country: United States
Website: https://traverspainting.com

Find You Houses Real Estate Inc. Launches Data-Driven, Personalized Approach to the Homebuying Process

New model emphasizes analytics, property insight, and client-centric housing consultation across Calgary

Calgary, Canada – May 29, 2025 – Find You Houses Real Estate Inc., operating under EXP REALTY, today announced the rollout of its personalized, data-informed housing consultation model, which aims to simplify the often-stressful process of buying a home. The company’s refined approach positions agents as analytical housing consultants, offering more than traditional real estate support.

Photo of Liz Wong, company founder

Grounded in a clear vision – helping people find homes, not just houses – the new system uses location-specific data, neighborhood statistics, and future value projections to guide each client’s housing decision with clarity and insight.

Visualizing Life in a Home Before Purchase

A cornerstone of the firm’s model is its client-specific analytics questionnaire, which evaluates personal needs alongside property potential. Whether through physical walkthroughs or immersive virtual tours, clients can preview what living in a home would feel like, making their choice more informed and emotionally aligned.

“Today’s buyers need more than listings; they need a partner who understands both data and human needs,” said Find You Houses Real Estate Inc. founder Liz Wong. “We act as matchmakers for housing by analyzing each home’s history, lifestyle fit, and long-term value for the owner.”

Shifting From Sales to Service

This model moves away from a buy-and-sell mentality, instead framing homebuying as a guided experience rooted in trust and transparency. With more than 14,000 homes viewed across Calgary and surrounding areas, Find You Houses Real Estate Inc. has built a process grounded in statistics, persistence, and asset protection.

Agents examine not only the buyer’s preferences but also broader market indicators to evaluate which properties are more likely to appreciate over time. The company’s framework aims to give clients a sense of confidence and control, grounded in knowledge and choice.

Building Community Through Referral Networks

In line with its people-focused approach, Find You Houses Real Estate Inc. also supports a growing network of professional referrals, connecting clients with trusted real estate experts aligned with the company’s vision and standards.

To schedule a consultation or learn more about the referral program, visit https://findyouhouses.com.

About Find You Houses Real Estate Inc. (Operates under EXP REALTY)

Find You Houses Real Estate Inc. is a Calgary-based firm dedicated to offering client-first, analytics-powered real estate consultation. Operating under EXP REALTY, the company focuses on helping clients discover homes tailored to their lives, using data, insight, and integrity at every step.

Media Contact
Company Name: Find You Houses Real Estate Inc. (Operates under EXP REALTY)
Contact Person: Liz Wong
Email: Send Email
Phone: +1 587 719 9664
Country: Canada
Website: https://findyouhouses.com/

Excaliblades Brings Chef-Level Precision to Everyday Kitchens with its Line of Professional-Grade Knives

Dallas, TX – May 29, 2025 – Excaliblades, a family-owned company specializing in high-performance kitchen cutlery, is making chef-level tools more accessible to everyday cooks with its line of premium, stainless steel knives. Designed with both form and function in mind, the brand’s products are engineered to deliver professional-grade performance, durability, and precision at a price point that fits the modern home kitchen.

Excaliblades Damascus Chef Knife

Excaliblades’ best-selling product, the Damascus Chef Knife, combines the sharpness and balance of a professional tool with the durability needed for daily use. It’s forged from 67 layers of VG-10 high-carbon stainless steel and features a striking Damascus-style pattern, offering precise cuts, rust resistance, and lasting edge retention. This is paired with a G10 epoxy resin handle with a black-and-turquoise finish for a comfortable grip and ergonomic balance.

“Our mission is to empower home cooks to prepare meals with the confidence and precision of a professional chef,” said Curtis and Christy Silverberg, the founders of Excaliblades. “We believe that high-quality kitchen tools shouldn’t be out of reach for the average household. Excaliblades was built to close that gap.”

All Excaliblades’ knives are dishwasher-safe, rustproof, and designed for long-term use. From chopping vegetables to slicing meats and filleting fish, the brand’s products are designed to handle a wide range of culinary tasks with ease. In addition, the company backs every knife with a lifetime warranty and responsive, customer-first service.

By offering knives that combine chef-level functionality with accessible pricing, Excaliblades is carving out a unique space in the kitchenware market – one that appeals to a growing community of home cooks who value both performance and affordability.

As the demand rises for functional, attractive, and affordable kitchen gear, Excaliblades continues to expand its reach while delivering exceptional quality and honest pricing. The brand’s vision remains the same: to make premium kitchen tools approachable for anyone who loves to cook.

To learn more about Excaliblades or to explore the brand’s full product lineup, please visit https://www.Excaliblades.com.

About Excaliblades

Excaliblades is a family-owned kitchen cutlery brand dedicated to making professional-grade knives accessible to everyday cooks. Combining premium materials, ergonomic design, and lifetime durability, Excaliblades empowers home chefs to prep with confidence without the premium price tag

Socials: Instagram, TikTok, Facebook

Media Contact
Company Name: Excaliblades
Contact Person: Curtis and Christy Silverberg
Email: Send Email
Phone: (469) 744-3156
Country: United States
Website: https://www.Excaliblades.com

Meet DRIFT3R, the Atlanta-Based Studio Putting an Art Gallery on Clothing

Each design from DRIFT3R tells a unique story through fashion apparel

Meet DRIFT3R, the Atlanta, Georgia, based fashion studio unlike any other. This fashion brand is truly an art gallery on clothing, offering a unique blend of art and fashion apparel that early wearers are excited about.

DRIFT3R got its start several years ago when creative director and designer Emil Jones found his love for art in elementary school. In 2023, he finally decided it was time to put some of his art on clothing. This is the culmination for all of the designs at DRIFT3R today, especially with the launch of the new Kinfolk collection.

Each of the pieces – or “symbols”, as Jones describes them – found in the Kinfolk collection has its own story. Each story is told raw and without filter, relating back to Jones’ own life and experiences. His hardships and ups and downs in life are what brought the Kinfolk collection to life. According to Jones, the new collection and all the designs at DRIFT3R reflect an atypical love story. In the Kinfolk collection, a blend of dark art and contrasting beauty, a story paints a picture while drawing parallels to the tale of a fallen angel.

For Jones, the art of his project shines through, but the production quality of his garments are highly prioritized. Each piece is made in the United States with hand-sewn labels, embroidery, and carefully-crafted signature amulets. When choosing materials, Jones wants his art to meet an equally fine canvas. “One can’t go without the other,” said Jones.

The collection is considered streetwear, however, when looking at Jones’ social media, Jones styles his garments in so many versatile ways, for women and men. DRIFT3R is truly a unique brand that can’t be placed in just one fashion category. Learn more now by visiting https://www.drift3r.com/.

ABOUT DRIFT3R

DRIFT3R is an Atlanta, Georgia, based fashion and design studio creating made-in-the-U.S. apparel, with each piece representing a unique piece of art that tells a story. Follow on social media:

Instagram: @drift3rcemona

Facebook: @drift3rcemona

TikTok: @drift3rcemona

Media Contact
Company Name: DRIFT3R
Email: Send Email
City: ATLANTA
State: GEORGIA
Country: United States
Website: https://www.drift3r.com/

Upfront Home Inspections Helps Clients Avoid Costly Mistakes While Purchasing Homes

A home is arguably the most significant purchase a person can make, and it makes sense to get the best possible value for the investment. Certified Master Inspector Jason Guillen ensures his clients don’t purchase properties that will result in substantial repair costs after closing.

Jason Guillen lives a life of service—first to his country as a proud U.S. Army veteran and now as a certified master inspector operating Upfront Home Inspections (UHI). Guillen ensures his clients are aware of any potential issues with a property before purchasing. Homebuyers in west central Florida have a reliable, trustworthy source for comprehensive and detailed home inspections.

“As a veteran-owned and operated business, we take pride in our thorough and meticulous approach to inspections,” said UHI Founder Jason Guillen. “Our comprehensive range of services includes everything from four-point insurance inspections to water testing and more, tailored to meet your needs.”

Upfront Home Inspections is the ideal solution for thorough pre-purchase home inspections and real estate inspection services in west central Florida and surrounding areas. Skip the hassle of scouring the internet with searches like “home inspection services near me” and choose a company with the necessary certifications and expertise upfront, alongside uncompromising integrity and a commitment to excellence.

“Whether you’re looking to improve your current home or make an informed decision about a new property, you can trust us to provide expert guidance and valuable insights,” Guillen said.

UHI serves clients in Hillsborough, Pasco, Hernando, Pinellas, Marion, Citrus, Sumter, and Lake Counties in Florida. The company sends licensed and insured experts to inspect single-family homes, townhouses, condos, manufactured homes, and other real estate properties.

UHI’s detailed home inspection checklist and report often reveal significant issues before clients sign on the dotted line and become responsible for repairs. Recently, Guillen saved a first-time homebuyer from unknowingly buying a home that needed $50,000 in work. Many satisfied customers left reviews with similar stories about the exemplary service they received throughout the property inspection process. Clients frequently mention UHI’s professionalism, detailed reports, and willingness to answer questions.

UHI connects clients with a certified master inspector who can handle any residential property inspection from foundation to flashing. UHI’s experienced team offers home inspections for: mold, wood destroying organisms (WDO), pools, VA/FHA water testing, roof certifications, wind mitigation, insurance, and more.

“Trust us to provide detailed insights, expert guidance, and thorough evaluations,” Guillen said. “At UHI, we understand the unique challenges and concerns that come with homeownership and the buying process, which is why we are committed to providing exceptional home inspection services that surpass typical standards.”

Visit the Upfront Home Inspections website to learn more about the company or to schedule a home inspection. Follow UHI on Facebook and Instagram for social media updates and learn more about the company’s support of K9s for Warriors to help end veteran suicide.

Media Contact
Company Name: Upfront Home Inspections
Contact Person: Jason Guillen
Email: Send Email
Country: United States
Website: http://www.upfronthomeinspections.net

PopStream Launches Desktop AR Broadcasting Platform for Windows Users Worldwide

PopStream, a Finnish-based technology company, has officially launched its augmented reality broadcasting platform for Windows users globally. The software enables content creators, educators, and professionals to integrate augmented reality elements directly into their video feeds without the need for post-production or additional hardware

PopStream installs as a virtual camera on any Windows computer and is compatible with all major video platforms, including Zoom, Microsoft Teams, YouTube Live, OBS, and Twitch. By leveraging AR marker technology and playlist scheduling, the software allows users to display banners, animations, or sponsored content directly onto real-world environments using just a standard webcam.

The demand for real-time content personalization and brand monetization has rapidly increased with the rise of livestreaming, virtual meetings, and the global creator economy. PopStream’s platform provides a seamless solution that works out of the box, removing technical barriers that have traditionally limited AR broadcasting to enterprise studios or post-production workflows.

The software includes features such as marker-based ad triggering, playlist-based content rotation, and full resolution output support. PopStream’s real-time functionality gives users full control over their on-screen experience while maintaining compatibility with their preferred streaming tools.

PopStream was developed by a team of engineers and AR specialists in Finland. The company’s leadership includes Founder & CEO Piruz Chaman Afruz (Bruce Afruz) and Managing Partner Talat Erden. The technology was built with a focus on performance, simplicity, and the growing need for creators to monetize their content through visual experiences.

The release marks a milestone for the company as it expands its product offerings for the creator economy and digital communications sector. With its headquarters in Helsinki, PopStream aims to support content professionals across industries by delivering intuitive, professional-grade AR tools that integrate into existing workflows.

The PopStream desktop application is now available for free download on Windows via the company’s website. The macOS version is expected to follow in the near future.

For more information about PopStream and its features, visit below.

Media Contact
Company Name: PopStream
Contact Person: Piruz Chaman Afruz (Bruce Afruz)
Email: Send Email
Country: Finland
Website: https://popstream.net

The Bodhi Tree Strengthens Recovery Support Through Expert Lymphatic Drainage Massage

The Bodhi Tree offers patients outstanding recovery support through its highly acclaimed Lymphatic Drainage Massage.

The Bodhi Tree Holistic Health Solutions, located in Mission Valley, remains committed to healing and recovery through its specialized focus on Manual Lymphatic Drainage (MLD). Recognized for its gentle, detoxifying approach, MLD is the foundation of The Bodhi Tree’s wellness services, supporting individuals recovering from surgery, managing chronic health conditions, or seeking to improve immune function.

“The Bodhi Tree offers integrative services of Manual Lymphatic Drainage complemented by infrared therapy for enhanced lymphatic system detoxification, acceleration of tissue repair, and pain management,” said the owner and certified Lymphatic Therapist, Theresa Gamlin. “With more than nine years of experience, we assist clients in dealing with post-op edema, boosting immunity, lymphedema, lipedema, and detoxification of the body. Lymphatic drainage massage is a gentle, rhythmic technique used to encourage the flow of lymph fluid throughout the body.”

The Bodhi Tree offers highly personalized care in a non-clinical setting. Trained in the Vodder method, Theresa applies precise, rhythmic techniques that help stimulate the lymphatic system, reduce swelling, and enhance the body’s ability to heal naturally.

According to Theresa, this therapy can benefit clients who are healing from surgery or looking to reduce inflammation and fatigue. It supports the body’s natural ability to restore balance.

Clients at The Bodhi Tree commonly seek MLD for post-surgical recovery from BBL, liposuction, C-sections, and breast surgeries. The technique is also beneficial for individuals with Lymphedema, Lipedema, fibromyalgia, autoimmune disorders, and those seeking detoxification and wellness maintenance.

MLD is often paired with Infrared Therapy to amplify results. Infrared therapy helps widen lymphatic and blood vessels, promoting deeper drainage and detoxification. The combination therapy, known as MLD + Infrared, accelerates tissue repair, improves circulation, and encourages cellular renewal.

In addition to the core lymphatic services, Theresa has expanded her offerings to include Oncology Massage for clients undergoing or recovering from cancer treatments. With specialized training and experience in Lymphedema care, she offers sensitive, tailored support for those impacted by lymph node removal or related conditions.

Despite the growing range of therapeutic options, Manual Lymphatic Drainage remains the cornerstone of The Bodhi Tree’s mission—to provide meaningful, restorative care that empowers the body to heal itself.

The Bodhi Tree Holistic Health Solutions welcomes new clients seeking supportive care during recovery, chronic illness management, or detox.

For more information, visit:

https://thebodhitreeholistic.com and https://directory.klosetraining.com/

To view their Instagram page, visit https://www.instagram.com/thebodhitreeholistic.

About The Bodhi Tree Holistic Health Solutions

Located in the heart of Mission Valley, San Diego, The Bodhi Tree Holistic Health Solutions has become the preferred wellness center for those seeking Manual Lymphatic Drainage (MLD)for post-surgical recovery, immune support, and detoxification. Theresa Gamlin is the founder and lead therapist, trained in the Vodder method of Manual Lymphatic Drainage- a proven technique to reduce swelling, boost circulation, and enhance overall wellness.

Media Contact
Company Name: The Bodhi Tree Holistic Health Solutions
Contact Person: Theresa Gamlin
Email: Send Email
Phone: 619-784-4922
Address:2535 Camino Del Rio South Suite 100
City: San Diego
State: CA
Country: United States
Website: https://thebodhitreeholistic.com/

Microvascular Angina Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Yale University, Millennium Pharma, AstraZeneca, Sanofi

The Key Microvascular Angina Companies in the market include – NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others.

DelveInsight’s “Microvascular Angina Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Microvascular Angina, historical and forecasted epidemiology as well as the Microvascular Angina market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Microvascular Angina, offering comprehensive insights into the Microvascular Angina revenue trends, prevalence, and treatment landscape. The report delves into key Microvascular Angina statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Microvascular Angina therapies. Additionally, we cover the landscape of Microvascular Angina clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Microvascular Angina treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Microvascular Angina space.

To Know in detail about the Microvascular Angina market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Microvascular Angina Market Forecast

Some of the key facts of the Microvascular Angina Market Report:

The Microvascular Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Microvascular Angina Companies: NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others
Key Microvascular Angina Therapies: Zibotentan, Ranolazine, Percutaneous Coronary Intervention (PCI), Rosuvastatin, clopidogrel, and others
The Microvascular Angina market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Microvascular Angina pipeline products will significantly revolutionize the Microvascular Angina market dynamics.
Among patients with angina symptoms and positive non-invasive ischemia tests but no obstructive coronary artery disease (CAD), the median prevalence of suspected MVA is approximately 43%, with reported ranges between 33% and 65%.
When using specialized diagnostic tools such as invasive coronary reactivity tests or coronary flow reserve measurements, the median prevalence of suspected MVA is about 28%, ranging from 13.5% to 46.5%.
In studies employing both ischemia testing and evidence of impaired microvascular function, the median prevalence of definitive MVA is around 30%, with a range of 19.7% to 60%.

Microvascular Angina Overview

Microvascular Angina (MVA) — also known as cardiac syndrome X — is a type of chest pain (angina) caused by abnormalities or dysfunction in the small coronary arteries (microvasculature) that supply blood to the heart muscle. Unlike classic angina, which is usually due to blockages in large coronary arteries, MVA occurs even when the larger arteries appear normal on angiograms.

Get a Free sample for the Microvascular Angina Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/microvascular-angina-market

Microvascular Angina Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Microvascular Angina Epidemiology Segmentation:

The Microvascular Angina market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Microvascular Angina
Prevalent Cases of Microvascular Angina by severity
Gender-specific Prevalence of Microvascular Angina
Diagnosed Cases of Episodic and Chronic Microvascular Angina

Download the report to understand which factors are driving Microvascular Angina epidemiology trends @ Microvascular Angina Epidemiology Forecast

Microvascular Angina Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Microvascular Angina market or expected to get launched during the study period. The analysis covers Microvascular Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Microvascular Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Microvascular Angina Therapies and Key Companies

Zibotentan: NHS Greater Glasgow and Clyde
Ranolazine: Yale University
Percutaneous Coronary Intervention (PCI): Millennium Pharma
Rosuvastatin: AstraZeneca
clopidogrel: Sanofi

Discover more about therapies set to grab major Microvascular Angina market share @ Microvascular Angina Treatment Landscape

Microvascular Angina Market Drivers

High Prevalence of Non-Obstructive Angina
Advancements in Diagnostic Techniques
Increased Awareness and Recognition
Emergence of Targeted Therapies

Microvascular Angina Market Barriers

Diagnostic Challenges
Limited Treatment Options
Underrepresentation in Clinical Trials
Healthcare Provider Awareness

Scope of the Microvascular Angina Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Microvascular Angina Companies: NHS Greater Glasgow and Clyde, Yale University, Millennium Pharma, AstraZeneca, Sanofi, and others
Key Microvascular Angina Therapies: Zibotentan, Ranolazine, Percutaneous Coronary Intervention (PCI), Rosuvastatin, clopidogrel, and others
Microvascular Angina Therapeutic Assessment: Microvascular Angina current marketed and Microvascular Angina emerging therapies
Microvascular Angina Market Dynamics: Microvascular Angina market drivers and Microvascular Angina market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Microvascular Angina Unmet Needs, KOL’s views, Analyst’s views, Microvascular Angina Market Access and Reimbursement

To know more about Microvascular Angina companies working in the treatment market, visit @ Microvascular Angina Clinical Trials and Therapeutic Assessment

Table of Contents

1. Microvascular Angina Market Report Introduction

2. Executive Summary for Microvascular Angina

3. SWOT analysis of Microvascular Angina

4. Microvascular Angina Patient Share (%) Overview at a Glance

5. Microvascular Angina Market Overview at a Glance

6. Microvascular Angina Disease Background and Overview

7. Microvascular Angina Epidemiology and Patient Population

8. Country-Specific Patient Population of Microvascular Angina

9. Microvascular Angina Current Treatment and Medical Practices

10. Microvascular Angina Unmet Needs

11. Microvascular Angina Emerging Therapies

12. Microvascular Angina Market Outlook

13. Country-Wise Microvascular Angina Market Analysis (2019–2032)

14. Microvascular Angina Market Access and Reimbursement of Therapies

15. Microvascular Angina Market Drivers

16. Microvascular Angina Market Barriers

17. Microvascular Angina Appendix

18. Microvascular Angina Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microvascular Angina Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Yale University, Millennium Pharma, AstraZeneca, Sanofi

Dyslipidemia With Hypertension Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Jeil Pharm., Chong Kun Dang Pharma, Daewoong Pharma, JW Pharma, Novartis

The Key Dyslipidemia With Hypertension Companies in the market include – Jeil Pharmaceutical Co., Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical Co., JW Pharmaceutical, Novartis, Yuhan Corporation, Hanmi Pharmaceutical, Boehringer Ingelheim, IlDong Pharmaceutical, and others.

DelveInsight’s “Dyslipidemia With Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dyslipidemia With Hypertension, historical and forecasted epidemiology as well as the Dyslipidemia With Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dyslipidemia With Hypertension, offering comprehensive insights into the Dyslipidemia With Hypertension revenue trends, prevalence, and treatment landscape. The report delves into key Dyslipidemia With Hypertension statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dyslipidemia With Hypertension therapies. Additionally, we cover the landscape of Dyslipidemia With Hypertension clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dyslipidemia With Hypertension treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dyslipidemia With Hypertension space.

To Know in detail about the Dyslipidemia With Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia With Hypertension Market Forecast

Some of the key facts of the Dyslipidemia With Hypertension Market Report:

The Dyslipidemia With Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Dyslipidemia With Hypertension Companies: Jeil Pharmaceutical Co., Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical Co., JW Pharmaceutical, Novartis, Yuhan Corporation, Hanmi Pharmaceutical, Boehringer Ingelheim, IlDong Pharmaceutical, and others
Key Dyslipidemia With Hypertension Therapies: Rosuvastatin, D013, D326, D337, DWJ1276, LivaloVA, Duowell®, valsartan, Fluvastatin, Rosuampin 10/5mg, HCP1701, telmisartan, Telmisartan/Amlodipine, and others
The Dyslipidemia With Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dyslipidemia With Hypertension pipeline products will significantly revolutionize the Dyslipidemia With Hypertension market dynamics.
In 2022, the total prevalent cases of dyslipidemia in the 7MM were approximately 287.6 million, projected to increase to 303.6 million by 2032, reflecting an annual growth rate of 0.56%
The U.S. had the highest number of prevalent cases in 2022, with 143.5 million individuals affected
Among the 7MM, Italy reported the fewest cases, with 21.3 million prevalent cases in 2022.
The prevalence of dyslipidemia increases with age, particularly affecting individuals aged 50 and above

Dyslipidemia With Hypertension Overview

Dyslipidemia with Hypertension refers to the coexistence of two cardiovascular risk factors: Dyslipidemia is an abnormal amount of lipids (like cholesterol or triglycerides) in the blood, often characterized by high LDL (bad cholesterol), low HDL (good cholesterol), or high triglycerides.

Get a Free sample for the Dyslipidemia With Hypertension Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dyslipidemia-with-hypertension-market

Dyslipidemia With Hypertension Epidemiology

Dyslipidemia With Hypertension Epidemiology Segmentation:

The Dyslipidemia With Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Dyslipidemia With Hypertension
Prevalent Cases of Dyslipidemia With Hypertension by severity
Gender-specific Prevalence of Dyslipidemia With Hypertension
Diagnosed Cases of Episodic and Chronic Dyslipidemia With Hypertension

Download the report to understand which factors are driving Dyslipidemia With Hypertension epidemiology trends @ Dyslipidemia With Hypertension Epidemiology Forecast

Dyslipidemia With Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia With Hypertension market or expected to get launched during the study period. The analysis covers Dyslipidemia With Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Dyslipidemia With Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dyslipidemia With Hypertension Therapies and Key Companies

Rosuvastatin: Jeil Pharmaceutical Co.
D013, D326, D337: Chong Kun Dang Pharmaceutical
DWJ1276: Daewoong Pharmaceutical Co.
LivaloVA: JW Pharmaceutical
Duowell®: JW Pharmaceutical
valsartan, Fluvastatin: Novartis
Rosuampin 10/5mg: Yuhan Corporation
HCP1701: Hanmi Pharmaceutical
telmisartan: Boehringer Ingelheim
Telmisartan/Amlodipine: IlDong Pharmaceutical

Discover more about therapies set to grab major Dyslipidemia With Hypertension market share @ Dyslipidemia With Hypertension Treatment Landscape

Dyslipidemia With Hypertension Market Drivers

Rising Global Prevalence
Advancements in Combination Therapies
Technological Innovations
Preventive Healthcare Initiatives
Research and Development

Dyslipidemia With Hypertension Market Barriers

Medication Adherence
Economic Constraints
Healthcare Infrastructure Limitations
Cultural and Educational Barriers
Regulatory Hurdles

Scope of the Dyslipidemia With Hypertension Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dyslipidemia With Hypertension Companies: Jeil Pharmaceutical Co., Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical Co., JW Pharmaceutical, Novartis, Yuhan Corporation, Hanmi Pharmaceutical, Boehringer Ingelheim, IlDong Pharmaceutical, and others
Key Dyslipidemia With Hypertension Therapies: Rosuvastatin, D013, D326, D337, DWJ1276, LivaloVA, Duowell®, valsartan, Fluvastatin, Rosuampin 10/5mg, HCP1701, telmisartan, Telmisartan/Amlodipine, and others
Dyslipidemia With Hypertension Therapeutic Assessment: Dyslipidemia With Hypertension current marketed and Dyslipidemia With Hypertension emerging therapies
Dyslipidemia With Hypertension Market Dynamics: Dyslipidemia With Hypertension market drivers and Dyslipidemia With Hypertension market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dyslipidemia With Hypertension Unmet Needs, KOL’s views, Analyst’s views, Dyslipidemia With Hypertension Market Access and Reimbursement

To know more about Dyslipidemia With Hypertension companies working in the treatment market, visit @ Dyslipidemia With Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dyslipidemia With Hypertension Market Report Introduction

2. Executive Summary for Dyslipidemia With Hypertension

3. SWOT analysis of Dyslipidemia With Hypertension

4. Dyslipidemia With Hypertension Patient Share (%) Overview at a Glance

5. Dyslipidemia With Hypertension Market Overview at a Glance

6. Dyslipidemia With Hypertension Disease Background and Overview

7. Dyslipidemia With Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Dyslipidemia With Hypertension

9. Dyslipidemia With Hypertension Current Treatment and Medical Practices

10. Dyslipidemia With Hypertension Unmet Needs

11. Dyslipidemia With Hypertension Emerging Therapies

12. Dyslipidemia With Hypertension Market Outlook

13. Country-Wise Dyslipidemia With Hypertension Market Analysis (2019–2032)

14. Dyslipidemia With Hypertension Market Access and Reimbursement of Therapies

15. Dyslipidemia With Hypertension Market Drivers

16. Dyslipidemia With Hypertension Market Barriers

17. Dyslipidemia With Hypertension Appendix

18. Dyslipidemia With Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dyslipidemia With Hypertension Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Jeil Pharm., Chong Kun Dang Pharma, Daewoong Pharma, JW Pharma, Novartis

Hypereosinophilic Syndrome Market Revenue to Expand Significantly by 2032, States DelveInsight Report | GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca

The Key Hypereosinophilic Syndrome Companies in the market include – GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca, and others.

DelveInsight’s “Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypereosinophilic Syndrome, historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Hypereosinophilic Syndrome, offering comprehensive insights into the Hypereosinophilic Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Hypereosinophilic Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Hypereosinophilic Syndrome therapies. Additionally, we cover the landscape of Hypereosinophilic Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Hypereosinophilic Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Hypereosinophilic Syndrome space.

To Know in detail about the Hypereosinophilic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypereosinophilic Syndrome Market Forecast

Some of the key facts of the Hypereosinophilic Syndrome Market Report:

The Hypereosinophilic Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Hypereosinophilic Syndrome Companies: GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca, and others
Key Hypereosinophilic Syndrome Therapies: Depemokimab, Benralizumab, Mepolizumab, imatinib mesylate, Dasatinib (BMS-354825), ICS-LABA, and others
The Hypereosinophilic Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypereosinophilic Syndrome pipeline products will significantly revolutionize the Hypereosinophilic Syndrome market dynamics.
HES is a rare disorder, with prevalence estimates ranging from 0.36 to 6.3 cases per 100,000 individuals in the United States.
The age-adjusted incidence rate is estimated between 0.16 and 0.36 per 100,000 people.
NCBI
HES predominantly affects adults aged 20 to 50 years. There is a notable male predominance, with male-to-female ratios reported between 4:1 and 9:1.
Commonly affected organs include the skin, heart, lungs, and nervous system.
BioMed Central
While less common, pediatric cases of HES have been reported, with children often presenting with higher eosinophil counts and more gastrointestinal symptoms compared to adults.

Hypereosinophilic Syndrome Overview

Hypereosinophilic Syndrome (HES) is a rare blood disorder characterized by persistently high levels of eosinophils (a type of white blood cell) in the blood and tissues. This overproduction of eosinophils can lead to inflammation and damage in various organs, including the heart, lungs, skin, and nervous system. HES can present with a wide range of symptoms, such as fatigue, cough, rash, shortness of breath, or even life-threatening complications. It may be caused by genetic mutations, underlying cancers, or remain idiopathic (unknown cause). Treatment typically involves corticosteroids, targeted therapies, or immunomodulatory drugs to control eosinophil levels and prevent organ damage.

Get a Free sample for the Hypereosinophilic Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market

Hypereosinophilic Syndrome Epidemiology

Hypereosinophilic Syndrome Epidemiology Segmentation:

The Hypereosinophilic Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Hypereosinophilic Syndrome
Prevalent Cases of Hypereosinophilic Syndrome by severity
Gender-specific Prevalence of Hypereosinophilic Syndrome
Diagnosed Cases of Episodic and Chronic Hypereosinophilic Syndrome

Download the report to understand which factors are driving Hypereosinophilic Syndrome epidemiology trends @ Hypereosinophilic Syndrome Epidemiology Forecast

Hypereosinophilic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypereosinophilic Syndrome market or expected to get launched during the study period. The analysis covers Hypereosinophilic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Hypereosinophilic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypereosinophilic Syndrome Therapies and Key Companies

Depemokimab: GlaxoSmithKline
Benralizumab: AstraZeneca
Mepolizumab: GlaxoSmithKline
imatinib mesylate: Novartis
Dasatinib (BMS-354825): M.D. Anderson Cancer Center
ICS-LABA: AstraZeneca

Discover more about therapies set to grab major Hypereosinophilic Syndrome market share @ Hypereosinophilic Syndrome Treatment Landscape

Hypereosinophilic Syndrome Market Drivers

Rising awareness and early diagnosis of hemophilia with inhibitors
Increasing adoption of novel bypassing agents and non-factor therapies (e.g., emicizumab)
Advancements in gene therapy research and development
Growing patient access to specialized hemophilia treatment centers
Supportive healthcare policies and reimbursement for high-cost therapies

Hypereosinophilic Syndrome Market Barriers

High treatment costs and limited affordability in many regions
Complex management requiring specialized care and monitoring
Limited availability of advanced therapies in low- and middle-income countries
Risk of adverse events and immune responses with some emerging treatments
Challenges in patient adherence to intensive treatment regimens

Scope of the Hypereosinophilic Syndrome Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypereosinophilic Syndrome Companies: GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca, and others
Key Hypereosinophilic Syndrome Therapies: Depemokimab, Benralizumab, Mepolizumab, imatinib mesylate, Dasatinib (BMS-354825), ICS-LABA, and others
Hypereosinophilic Syndrome Therapeutic Assessment: Hypereosinophilic Syndrome current marketed and Hypereosinophilic Syndrome emerging therapies
Hypereosinophilic Syndrome Market Dynamics: Hypereosinophilic Syndrome market drivers and Hypereosinophilic Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hypereosinophilic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Hypereosinophilic Syndrome Market Access and Reimbursement

To know more about Hypereosinophilic Syndrome companies working in the treatment market, visit @ Hypereosinophilic Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hypereosinophilic Syndrome Market Report Introduction

2. Executive Summary for Hypereosinophilic Syndrome

3. SWOT analysis of Hypereosinophilic Syndrome

4. Hypereosinophilic Syndrome Patient Share (%) Overview at a Glance

5. Hypereosinophilic Syndrome Market Overview at a Glance

6. Hypereosinophilic Syndrome Disease Background and Overview

7. Hypereosinophilic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypereosinophilic Syndrome

9. Hypereosinophilic Syndrome Current Treatment and Medical Practices

10. Hypereosinophilic Syndrome Unmet Needs

11. Hypereosinophilic Syndrome Emerging Therapies

12. Hypereosinophilic Syndrome Market Outlook

13. Country-Wise Hypereosinophilic Syndrome Market Analysis (2019–2032)

14. Hypereosinophilic Syndrome Market Access and Reimbursement of Therapies

15. Hypereosinophilic Syndrome Market Drivers

16. Hypereosinophilic Syndrome Market Barriers

17. Hypereosinophilic Syndrome Appendix

18. Hypereosinophilic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypereosinophilic Syndrome Market Revenue to Expand Significantly by 2032, States DelveInsight Report | GlaxoSmithKline, AstraZeneca, Novartis, M.D. Anderson Cancer Center, AstraZeneca